Patients were treated. Patients were treated. All 10 patients were treated by radical prostatectomy or-gan – confined disease with one exception. 4 of treated patients after treatment had a median follow error in follow-up of 48 months.. Results: Median age at diagnosis was 67 years. Median follow-up was 76 months. Overall, 34 patients had progression. Overall, median time to progression was 18 months. The first re – biopsy was positive for cancer in 48 patients and negative in 44 patients. The 5-year actuarial progression-free probability was 82 percent for patients with negative first , compared to 50 percent of patients with positive first re – biopsy and re – biopsy, it was 97 percent for patients with persistent negative biopsy compared to 42 percent in patients with persistent positive biopsy (p2 positive cores at diagnosis were significant predictor of progression.
Conclusions: Negative in patients with prostate cancer on AS low volume disease re – biopsy has the result of the first repeated biopsy strong impact. In the prediction of progression of the disease. Patients with positive first re – biopsy should be taken into consideration for treatment. Pathological progression usually occurs in the first 2 years of follow up. Intensive biopsy protocol in the first 2-3 years is required to recognize and provide treatment to patients at high risk of progression.Winston Laboratories studied activated looking for a partner by sales and marketing strength commercialize recent civamide polish 0.
Civamide is an investigational and from the U.S. Food by the U.S. Food and Drug Administration for any clinical indications yet.